- Home
- NEOV vs PLX Comparison
NEOV vs PLX Comparison
Compare NEOV & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- PLX
- Stock Information
- Founded
- NEOV 2018
- PLX 1993
- Country
- NEOV United States
- PLX United States
- Employees
- NEOV N/A
- PLX N/A
- Industry
- NEOV Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEOV Miscellaneous
- PLX Health Care
- Exchange
- NEOV Nasdaq
- PLX Nasdaq
- Market Cap
- NEOV 153.9M
- PLX 127.4M
- IPO Year
- NEOV N/A
- PLX 1998
- Fundamental
- Price
- NEOV $5.20
- PLX $1.91
- Analyst Decision
- NEOV Strong Buy
- PLX Strong Buy
- Analyst Count
- NEOV 1
- PLX 1
- Target Price
- NEOV $7.50
- PLX $15.00
- AVG Volume (30 Days)
- NEOV 236.7K
- PLX 705.4K
- Earning Date
- NEOV 11-07-2025
- PLX 11-13-2025
- Dividend Yield
- NEOV N/A
- PLX N/A
- EPS Growth
- NEOV N/A
- PLX N/A
- EPS
- NEOV N/A
- PLX 0.08
- Revenue
- NEOV $4,255,136.00
- PLX $61,948,000.00
- Revenue This Year
- NEOV $208.50
- PLX $14.53
- Revenue Next Year
- NEOV $128.75
- PLX $75.77
- P/E Ratio
- NEOV N/A
- PLX $24.60
- Revenue Growth
- NEOV 52.64
- PLX 62.79
- 52 Week Low
- NEOV $1.80
- PLX $0.99
- 52 Week High
- NEOV $6.11
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- NEOV 68.69
- PLX 70.20
- Support Level
- NEOV $3.40
- PLX $1.52
- Resistance Level
- NEOV $3.86
- PLX $1.69
- Average True Range (ATR)
- NEOV 0.35
- PLX 0.08
- MACD
- NEOV 0.19
- PLX 0.03
- Stochastic Oscillator
- NEOV 89.60
- PLX 91.67
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.